Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05152147




Registration number
NCT05152147
Ethics application status
Date submitted
5/11/2021
Date registered
9/12/2021
Date last updated
18/11/2024

Titles & IDs
Public title
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Scientific title
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Secondary ID [1] 0 0
2021-000296-36
Secondary ID [2] 0 0
ZWI-ZW25-301
Universal Trial Number (UTN)
Trial acronym
HERIZON-GEA-01
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastric Neoplasms 0 0
Gastroesophageal Adenocarcinoma 0 0
Esophageal Adenocarcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Zanidatamab
Treatment: Drugs - Tislelizumab
Treatment: Drugs - Trastuzumab
Treatment: Drugs - Capecitabine
Treatment: Drugs - Oxaliplatin
Treatment: Drugs - Cisplatin
Treatment: Drugs - 5-Fluorouracil

Active comparator: Arm A - Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)

Experimental: Arm B - Zanidatamab plus physician's choice of CAPOX or FP

Experimental: Arm C - Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP


Treatment: Drugs: Zanidatamab
Administered IV

Treatment: Drugs: Tislelizumab
Administered IV

Treatment: Drugs: Trastuzumab
Administered intravenously (IV)

Treatment: Drugs: Capecitabine
Administered orally (PO bid)

Treatment: Drugs: Oxaliplatin
Administered IV

Treatment: Drugs: Cisplatin
Administered IV

Treatment: Drugs: 5-Fluorouracil
Administered IV
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free survival (PFS) by BICR
Timepoint [1] 0 0
Up to 2.5 years
Primary outcome [2] 0 0
Overall survival
Timepoint [2] 0 0
Up to 3.5 years
Secondary outcome [1] 0 0
Confirmed objective response rate (ORR) by BICR
Timepoint [1] 0 0
Up to 2.5 years
Secondary outcome [2] 0 0
Duration of response (DOR) by BICR
Timepoint [2] 0 0
Up to 2.5 years
Secondary outcome [3] 0 0
PFS per Investigator assessment
Timepoint [3] 0 0
Up to 2.5 years
Secondary outcome [4] 0 0
Confirmed ORR per Investigator assessment
Timepoint [4] 0 0
Up to 2.5 years
Secondary outcome [5] 0 0
DOR per Investigator assessment
Timepoint [5] 0 0
Up to 2.5 years
Secondary outcome [6] 0 0
Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR
Timepoint [6] 0 0
Up to 2.5 years
Secondary outcome [7] 0 0
Assessment of Contribution of Components based on Overall Survival
Timepoint [7] 0 0
Up to 3.5 years
Secondary outcome [8] 0 0
Incidence of adverse events
Timepoint [8] 0 0
Up to 2 years
Secondary outcome [9] 0 0
Incidence of clinical laboratory abnormalities
Timepoint [9] 0 0
Up to 2 years
Secondary outcome [10] 0 0
Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)
Timepoint [10] 0 0
Up to 2.5 years
Secondary outcome [11] 0 0
HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)
Timepoint [11] 0 0
Up to 2.5 years
Secondary outcome [12] 0 0
HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire
Timepoint [12] 0 0
Up to 2.5 years
Secondary outcome [13] 0 0
Serum concentration of zanidatamab and tislelizumab
Timepoint [13] 0 0
Up to 2 years
Secondary outcome [14] 0 0
Incidence of anti-drug antibodies (ADAs)
Timepoint [14] 0 0
Up to 2 years

Eligibility
Key inclusion criteria
* Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
* Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
* Adequate organ function
* Left ventricular ejection fraction (LVEF) = 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
* Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
* Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
* Known history of or ongoing leptomeningeal disease (LMD)
* Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
* Known active hepatitis
* Any history of human immunodeficiency virus (HIV) infection
* Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
* QTc Fridericia (QTcF) > 470 ms
* Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2025
Actual
Sample size
Target
918
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Border Medical Oncology Research Unit - Albury
Recruitment hospital [2] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [3] 0 0
Austin Health - Heidelberg
Recruitment hospital [4] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [5] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2640 - Albury
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
2170 - Liverpool
Recruitment postcode(s) [5] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Ciudad Autónoma de Buenos Aires
Country [3] 0 0
Argentina
State/province [3] 0 0
Córdoba
Country [4] 0 0
Argentina
State/province [4] 0 0
Pergamino
Country [5] 0 0
Argentina
State/province [5] 0 0
San Miguel De Tucumán
Country [6] 0 0
Argentina
State/province [6] 0 0
Viedma
Country [7] 0 0
Belgium
State/province [7] 0 0
Bonheiden
Country [8] 0 0
Belgium
State/province [8] 0 0
Brussels
Country [9] 0 0
Belgium
State/province [9] 0 0
Gent
Country [10] 0 0
Belgium
State/province [10] 0 0
Leuven
Country [11] 0 0
Belgium
State/province [11] 0 0
Liège
Country [12] 0 0
Brazil
State/province [12] 0 0
Bahia
Country [13] 0 0
Brazil
State/province [13] 0 0
Rondonia
Country [14] 0 0
Brazil
State/province [14] 0 0
Sao Paolo
Country [15] 0 0
Brazil
State/province [15] 0 0
Vitoria
Country [16] 0 0
Brazil
State/province [16] 0 0
Barretos
Country [17] 0 0
Brazil
State/province [17] 0 0
Belo Horizonte
Country [18] 0 0
Brazil
State/province [18] 0 0
Brasília
Country [19] 0 0
Brazil
State/province [19] 0 0
Fortaleza
Country [20] 0 0
Brazil
State/province [20] 0 0
Ijuí
Country [21] 0 0
Brazil
State/province [21] 0 0
Porto Alegre
Country [22] 0 0
Brazil
State/province [22] 0 0
Rio De Janeiro
Country [23] 0 0
Brazil
State/province [23] 0 0
Santo André
Country [24] 0 0
Brazil
State/province [24] 0 0
Sorocaba
Country [25] 0 0
Brazil
State/province [25] 0 0
São Paulo
Country [26] 0 0
Canada
State/province [26] 0 0
Toronto
Country [27] 0 0
Chile
State/province [27] 0 0
Región-Metropolitana De Santiago
Country [28] 0 0
Chile
State/province [28] 0 0
Osorno
Country [29] 0 0
Chile
State/province [29] 0 0
Providencia
Country [30] 0 0
Chile
State/province [30] 0 0
Recoleta
Country [31] 0 0
Chile
State/province [31] 0 0
Santiago
Country [32] 0 0
Chile
State/province [32] 0 0
Temuco
Country [33] 0 0
China
State/province [33] 0 0
Beijing
Country [34] 0 0
China
State/province [34] 0 0
Bengbu
Country [35] 0 0
China
State/province [35] 0 0
Changsha
Country [36] 0 0
China
State/province [36] 0 0
Changzhi
Country [37] 0 0
China
State/province [37] 0 0
Changzhou
Country [38] 0 0
China
State/province [38] 0 0
Chengdu
Country [39] 0 0
China
State/province [39] 0 0
Foshan
Country [40] 0 0
China
State/province [40] 0 0
Fuzhou
Country [41] 0 0
China
State/province [41] 0 0
Guangzhou
Country [42] 0 0
China
State/province [42] 0 0
Haikou
Country [43] 0 0
China
State/province [43] 0 0
Hangzhou
Country [44] 0 0
China
State/province [44] 0 0
Harbin
Country [45] 0 0
China
State/province [45] 0 0
Hefei
Country [46] 0 0
China
State/province [46] 0 0
Hohhot
Country [47] 0 0
China
State/province [47] 0 0
Jinan
Country [48] 0 0
China
State/province [48] 0 0
Kunming
Country [49] 0 0
China
State/province [49] 0 0
Lanzhou
Country [50] 0 0
China
State/province [50] 0 0
Nanchang
Country [51] 0 0
China
State/province [51] 0 0
Nanjing
Country [52] 0 0
China
State/province [52] 0 0
Qingdao
Country [53] 0 0
China
State/province [53] 0 0
Shanghai
Country [54] 0 0
China
State/province [54] 0 0
Shangrao
Country [55] 0 0
China
State/province [55] 0 0
Shenyang
Country [56] 0 0
China
State/province [56] 0 0
Shenzhen
Country [57] 0 0
China
State/province [57] 0 0
Shijiazhuang
Country [58] 0 0
China
State/province [58] 0 0
Tianjin
Country [59] 0 0
China
State/province [59] 0 0
Tonghua
Country [60] 0 0
China
State/province [60] 0 0
Weihai
Country [61] 0 0
China
State/province [61] 0 0
Wenzhou
Country [62] 0 0
China
State/province [62] 0 0
Wuhan
Country [63] 0 0
China
State/province [63] 0 0
Wuxi
Country [64] 0 0
China
State/province [64] 0 0
Xi'an
Country [65] 0 0
China
State/province [65] 0 0
Xiamen
Country [66] 0 0
China
State/province [66] 0 0
Yangzhou
Country [67] 0 0
China
State/province [67] 0 0
Zhengzhou
Country [68] 0 0
China
State/province [68] 0 0
Ürümqi
Country [69] 0 0
Czechia
State/province [69] 0 0
Hradec Králové
Country [70] 0 0
Estonia
State/province [70] 0 0
Tallinn
Country [71] 0 0
France
State/province [71] 0 0
Gironde
Country [72] 0 0
France
State/province [72] 0 0
Avignon
Country [73] 0 0
France
State/province [73] 0 0
Besançon
Country [74] 0 0
France
State/province [74] 0 0
Bordeaux
Country [75] 0 0
France
State/province [75] 0 0
Dijon
Country [76] 0 0
France
State/province [76] 0 0
Grenoble
Country [77] 0 0
France
State/province [77] 0 0
Lyon
Country [78] 0 0
France
State/province [78] 0 0
Nantes
Country [79] 0 0
France
State/province [79] 0 0
Poitiers
Country [80] 0 0
France
State/province [80] 0 0
Rennes
Country [81] 0 0
France
State/province [81] 0 0
Saint-Priest-en-Jarez
Country [82] 0 0
France
State/province [82] 0 0
Toulouse
Country [83] 0 0
France
State/province [83] 0 0
Villejuif
Country [84] 0 0
Georgia
State/province [84] 0 0
Tbilisi
Country [85] 0 0
Germany
State/province [85] 0 0
Hessen
Country [86] 0 0
Germany
State/province [86] 0 0
Rheinland-Pfalz
Country [87] 0 0
Germany
State/province [87] 0 0
Hannover
Country [88] 0 0
Germany
State/province [88] 0 0
Leipzig
Country [89] 0 0
Germany
State/province [89] 0 0
Ulm
Country [90] 0 0
Greece
State/province [90] 0 0
Attiki
Country [91] 0 0
Greece
State/province [91] 0 0
Athens
Country [92] 0 0
Greece
State/province [92] 0 0
Piraeus
Country [93] 0 0
Greece
State/province [93] 0 0
Thessaloniki
Country [94] 0 0
Guatemala
State/province [94] 0 0
Guatemala City
Country [95] 0 0
Guatemala
State/province [95] 0 0
Salcaja
Country [96] 0 0
India
State/province [96] 0 0
Bangalore
Country [97] 0 0
India
State/province [97] 0 0
Bhubaneswar
Country [98] 0 0
India
State/province [98] 0 0
Gurgaon
Country [99] 0 0
India
State/province [99] 0 0
Hyderabad
Country [100] 0 0
India
State/province [100] 0 0
Jaipur
Country [101] 0 0
India
State/province [101] 0 0
Nashik
Country [102] 0 0
India
State/province [102] 0 0
New Delhi
Country [103] 0 0
India
State/province [103] 0 0
Patna
Country [104] 0 0
India
State/province [104] 0 0
Pune
Country [105] 0 0
India
State/province [105] 0 0
Vijayawada
Country [106] 0 0
Ireland
State/province [106] 0 0
Dublin
Country [107] 0 0
Italy
State/province [107] 0 0
Bologna
Country [108] 0 0
Italy
State/province [108] 0 0
Candiolo
Country [109] 0 0
Italy
State/province [109] 0 0
Genova
Country [110] 0 0
Italy
State/province [110] 0 0
Meldola
Country [111] 0 0
Italy
State/province [111] 0 0
Milano
Country [112] 0 0
Italy
State/province [112] 0 0
Modena
Country [113] 0 0
Italy
State/province [113] 0 0
Reggio Emilia
Country [114] 0 0
Italy
State/province [114] 0 0
Rome
Country [115] 0 0
Italy
State/province [115] 0 0
Torino
Country [116] 0 0
Italy
State/province [116] 0 0
Verona
Country [117] 0 0
Italy
State/province [117] 0 0
Vicenza
Country [118] 0 0
Japan
State/province [118] 0 0
Gihu
Country [119] 0 0
Japan
State/province [119] 0 0
Gunma
Country [120] 0 0
Japan
State/province [120] 0 0
Hukui
Country [121] 0 0
Japan
State/province [121] 0 0
Hyôgo
Country [122] 0 0
Japan
State/province [122] 0 0
Ibaraki
Country [123] 0 0
Japan
State/province [123] 0 0
Kagawa
Country [124] 0 0
Japan
State/province [124] 0 0
Kanagawa
Country [125] 0 0
Japan
State/province [125] 0 0
Kumamoto
Country [126] 0 0
Japan
State/province [126] 0 0
Kyoto-shi
Country [127] 0 0
Japan
State/province [127] 0 0
Miyagi
Country [128] 0 0
Japan
State/province [128] 0 0
Okayama
Country [129] 0 0
Japan
State/province [129] 0 0
Osaka
Country [130] 0 0
Japan
State/province [130] 0 0
Tiba
Country [131] 0 0
Japan
State/province [131] 0 0
Tokyo
Country [132] 0 0
Japan
State/province [132] 0 0
Chuo Ku
Country [133] 0 0
Japan
State/province [133] 0 0
Fukuoka-shi
Country [134] 0 0
Japan
State/province [134] 0 0
Ina
Country [135] 0 0
Japan
State/province [135] 0 0
Matsuyama
Country [136] 0 0
Japan
State/province [136] 0 0
Nagoya shi
Country [137] 0 0
Japan
State/province [137] 0 0
Niigata-shi
Country [138] 0 0
Japan
State/province [138] 0 0
Osaka-sayama
Country [139] 0 0
Japan
State/province [139] 0 0
Shizuoka
Country [140] 0 0
Korea, Republic of
State/province [140] 0 0
Anyang-si
Country [141] 0 0
Korea, Republic of
State/province [141] 0 0
Busan
Country [142] 0 0
Korea, Republic of
State/province [142] 0 0
Daegu
Country [143] 0 0
Korea, Republic of
State/province [143] 0 0
Goyang-si
Country [144] 0 0
Korea, Republic of
State/province [144] 0 0
Incheon
Country [145] 0 0
Korea, Republic of
State/province [145] 0 0
Seongnam-si
Country [146] 0 0
Korea, Republic of
State/province [146] 0 0
Seoul
Country [147] 0 0
Malaysia
State/province [147] 0 0
George Town
Country [148] 0 0
Malaysia
State/province [148] 0 0
Kuala Lumpur
Country [149] 0 0
Malaysia
State/province [149] 0 0
Kuching
Country [150] 0 0
Malaysia
State/province [150] 0 0
Putrajaya
Country [151] 0 0
Mexico
State/province [151] 0 0
Mexico City
Country [152] 0 0
Mexico
State/province [152] 0 0
Monterrey
Country [153] 0 0
Mexico
State/province [153] 0 0
Oaxaca
Country [154] 0 0
Netherlands
State/province [154] 0 0
Eindhoven
Country [155] 0 0
Netherlands
State/province [155] 0 0
Groningen
Country [156] 0 0
Netherlands
State/province [156] 0 0
Leiden
Country [157] 0 0
Netherlands
State/province [157] 0 0
Tilburg
Country [158] 0 0
Poland
State/province [158] 0 0
Skórzewo
Country [159] 0 0
Poland
State/province [159] 0 0
Warszawa
Country [160] 0 0
Poland
State/province [160] 0 0
Lódz
Country [161] 0 0
Portugal
State/province [161] 0 0
Almada
Country [162] 0 0
Portugal
State/province [162] 0 0
Coimbra
Country [163] 0 0
Portugal
State/province [163] 0 0
Guimarães
Country [164] 0 0
Portugal
State/province [164] 0 0
Lisboa
Country [165] 0 0
Portugal
State/province [165] 0 0
Loures
Country [166] 0 0
Portugal
State/province [166] 0 0
Matosinhos
Country [167] 0 0
Portugal
State/province [167] 0 0
Porto
Country [168] 0 0
Romania
State/province [168] 0 0
Bucure?ti
Country [169] 0 0
Romania
State/province [169] 0 0
Cluj-Napoca
Country [170] 0 0
Romania
State/province [170] 0 0
Craiova
Country [171] 0 0
Romania
State/province [171] 0 0
Iasi
Country [172] 0 0
Serbia
State/province [172] 0 0
Belgrade
Country [173] 0 0
Serbia
State/province [173] 0 0
Niš
Country [174] 0 0
Serbia
State/province [174] 0 0
Sremska Kamenica
Country [175] 0 0
Singapore
State/province [175] 0 0
Singapore
Country [176] 0 0
South Africa
State/province [176] 0 0
Cape Town
Country [177] 0 0
South Africa
State/province [177] 0 0
Mogale City
Country [178] 0 0
South Africa
State/province [178] 0 0
Pretoria
Country [179] 0 0
Spain
State/province [179] 0 0
Barcelona
Country [180] 0 0
Spain
State/province [180] 0 0
Navarra
Country [181] 0 0
Spain
State/province [181] 0 0
Badalona
Country [182] 0 0
Spain
State/province [182] 0 0
Girona
Country [183] 0 0
Spain
State/province [183] 0 0
L'Hospitalet de Llobregat
Country [184] 0 0
Spain
State/province [184] 0 0
Madrid
Country [185] 0 0
Spain
State/province [185] 0 0
Málaga
Country [186] 0 0
Spain
State/province [186] 0 0
Salamanca
Country [187] 0 0
Spain
State/province [187] 0 0
Santander
Country [188] 0 0
Spain
State/province [188] 0 0
Sevilla
Country [189] 0 0
Spain
State/province [189] 0 0
Valencia
Country [190] 0 0
Spain
State/province [190] 0 0
Zaragoza
Country [191] 0 0
Taiwan
State/province [191] 0 0
Taichung
Country [192] 0 0
Taiwan
State/province [192] 0 0
Tainan
Country [193] 0 0
Taiwan
State/province [193] 0 0
Taipei
Country [194] 0 0
Thailand
State/province [194] 0 0
Bangkok Noi
Country [195] 0 0
Thailand
State/province [195] 0 0
Bangkok
Country [196] 0 0
Thailand
State/province [196] 0 0
Hat Yai
Country [197] 0 0
Thailand
State/province [197] 0 0
Khon Kaen
Country [198] 0 0
Thailand
State/province [198] 0 0
Lak Si
Country [199] 0 0
Thailand
State/province [199] 0 0
Phitsanulok
Country [200] 0 0
Turkey
State/province [200] 0 0
Istanbul
Country [201] 0 0
Turkey
State/province [201] 0 0
Ankara
Country [202] 0 0
Turkey
State/province [202] 0 0
Antalya
Country [203] 0 0
Turkey
State/province [203] 0 0
Balçova
Country [204] 0 0
Turkey
State/province [204] 0 0
Bursa
Country [205] 0 0
Turkey
State/province [205] 0 0
Denizli
Country [206] 0 0
Turkey
State/province [206] 0 0
Diyarbakir
Country [207] 0 0
Turkey
State/province [207] 0 0
Edirne
Country [208] 0 0
Turkey
State/province [208] 0 0
Fatih
Country [209] 0 0
Turkey
State/province [209] 0 0
Izmir
Country [210] 0 0
Turkey
State/province [210] 0 0
Sariyer
Country [211] 0 0
Turkey
State/province [211] 0 0
Seyhan
Country [212] 0 0
Turkey
State/province [212] 0 0
Sur
Country [213] 0 0
Turkey
State/province [213] 0 0
Tarabya
Country [214] 0 0
Turkey
State/province [214] 0 0
Trabzon
Country [215] 0 0
Turkey
State/province [215] 0 0
Yenimahalle
Country [216] 0 0
Turkey
State/province [216] 0 0
Çankaya
Country [217] 0 0
Ukraine
State/province [217] 0 0
Dnipropetrovsk
Country [218] 0 0
Ukraine
State/province [218] 0 0
Kharkiv
Country [219] 0 0
Ukraine
State/province [219] 0 0
Kryvyi Rih
Country [220] 0 0
Ukraine
State/province [220] 0 0
Kyiv
Country [221] 0 0
Ukraine
State/province [221] 0 0
Lutsk
Country [222] 0 0
Ukraine
State/province [222] 0 0
Odesa
Country [223] 0 0
United Kingdom
State/province [223] 0 0
Bristol
Country [224] 0 0
United Kingdom
State/province [224] 0 0
Edinburgh
Country [225] 0 0
United Kingdom
State/province [225] 0 0
Leeds
Country [226] 0 0
United Kingdom
State/province [226] 0 0
London
Country [227] 0 0
United Kingdom
State/province [227] 0 0
Northwood
Country [228] 0 0
United Kingdom
State/province [228] 0 0
Peterborough
Country [229] 0 0
United Kingdom
State/province [229] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Jazz Pharmaceuticals
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
BeiGene, Ltd.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
Trial website
https://clinicaltrials.gov/study/NCT05152147
Trial related presentations / publications
Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep;18(29):3255-3266. doi: 10.2217/fon-2022-0595. Epub 2022 Aug 24.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Trial Disclosure & Transparency
Address 0 0
Country 0 0
Phone 0 0
215-832-3750
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05152147